Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

doi:10.1182/blood.2022016867

. 2022 Sep 22;140(12):1345-1377.

doi: 10.1182/blood.2022016867.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner¹, Andrew H Wei², Frederick R Appelbaum³, Charles Craddock⁴, Courtney D DiNardo⁵, Hervé Dombret⁶, Benjamin L Ebert⁷, Pierre Fenaux⁸, Lucy A Godley⁹, Robert P Hasserjian¹⁰, Richard A Larson¹¹, Ross L Levine¹², Yasushi Miyazaki¹³, Dietger Niederwieser¹⁴, Gert Ossenkoppele¹⁵, Christoph Röllig¹⁶, Jorge Sierra¹⁷, Eytan M Stein¹⁸, Martin S Tallman¹⁸, Hwei-Fang Tien¹⁹, Jianxiang Wang²⁰, Agnieszka Wierzbowska²¹, Bob Löwenberg²²

Affiliations

¹ Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
² Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.
³ University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA.
⁴ Centre for Clinical Haematology, Queen Elizabeth Hospital, University of Birminham, Birmingham, UK.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁶ Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Dana-Farber Cancer Institute, Boston, MA.
⁸ Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
¹⁰ Department of Pathology, Massachusetts General Hospital, Boston, MA.
¹¹ Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL.
¹² Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
¹³ Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
¹⁴ University of Leipzig, Leipzig, Germany.
¹⁵ Department of Haematology, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands.
¹⁶ Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
¹⁷ Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
¹⁸ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
¹⁹ Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
²⁰ Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
²¹ Department of Hematology, Medical University of Lodz, Lodz, Poland; and.
²² Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

PMID: 35797463
DOI: 10.1182/blood.2022016867

Free article

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner et al. Blood. 2022.

Free article

. 2022 Sep 22;140(12):1345-1377.

doi: 10.1182/blood.2022016867.

Authors

Affiliations

¹ Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
² Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.
³ University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA.
⁴ Centre for Clinical Haematology, Queen Elizabeth Hospital, University of Birminham, Birmingham, UK.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
⁶ Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁷ Dana-Farber Cancer Institute, Boston, MA.
⁸ Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁹ Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
¹⁰ Department of Pathology, Massachusetts General Hospital, Boston, MA.
¹¹ Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL.
¹² Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
¹³ Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
¹⁴ University of Leipzig, Leipzig, Germany.
¹⁵ Department of Haematology, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands.
¹⁶ Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
¹⁷ Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
¹⁸ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
¹⁹ Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
²⁰ Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
²¹ Department of Hematology, Medical University of Lodz, Lodz, Poland; and.
²² Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

PMID: 35797463
DOI: 10.1182/blood.2022016867

Abstract

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

PubMed Disclaimer

Comment in

How thinly can one slice the AML diagnostic pie?
Schiller G. Schiller G. Blood. 2022 Sep 22;140(12):1330-1331. doi: 10.1182/blood.2022017653. Blood. 2022. PMID: 36136361 No abstract available.

Cited by

A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.
Tseng S, Lee ME, Lin PC. Tseng S, et al. Pharmaceuticals (Basel). 2023 Nov 15;16(11):1614. doi: 10.3390/ph16111614. Pharmaceuticals (Basel). 2023. PMID: 38004478 Free PMC article. Review.
Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers.
Kang KW, Gim JA, Hong S, Kim HK, Choi Y, Park JH, Park Y. Kang KW, et al. PLoS One. 2024 Aug 23;19(8):e0306962. doi: 10.1371/journal.pone.0306962. eCollection 2024. PLoS One. 2024. PMID: 39178208 Free PMC article.
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
Root JL, Desai PN, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay S, Alfayez M, Matthews J, Pierce S, Reville PK, Daver N, Abbas HA. Root JL, et al. Cancer Res Commun. 2024 Mar 6;4(3):671-681. doi: 10.1158/2767-9764.CRC-23-0402. Cancer Res Commun. 2024. PMID: 38391202 Free PMC article.
Toward Standardization of Flow-Cytometric Immunophenotyping for the Diagnosis and Monitoring of Hematologic Malignancies.
Kim SY, Huh HJ. Kim SY, et al. Ann Lab Med. 2024 May 1;44(3):193-194. doi: 10.3343/alm.2023.0467. Epub 2023 Dec 26. Ann Lab Med. 2024. PMID: 38145894 Free PMC article. No abstract available.
Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.
Stefańczyk SA, Hayn C, Heitmann J, Jung S, Zekri L, Märklin M. Stefańczyk SA, et al. Cancers (Basel). 2024 Jul 4;16(13):2455. doi: 10.3390/cancers16132455. Cancers (Basel). 2024. PMID: 39001517 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Affiliations

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Miscellaneous

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Miscellaneous